Latest Breaking News On - American society of clinical oncology - Page 2 : comparemela.com

Study shows the HPV vaccine can prevent head and neck cancers, not just cervical cancer

HPV has also been linked to head and neck cancers in men. The researchers who did the study found that the vaccine can reduce the risk of getting these cancers by 50%.

United statesNational cancer instituteUs advisory committee on immunization practicesAmerican society of clinical oncologyUniversity of rochester medical centerAmerican societyClinical oncologyCynthia randRochester medicalImmunization practices

Tecvayli Responses Continue for Two Years in R/R Multiple Myeloma

Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year.

United statesAmerican society of clinical oncologyNational cancer instituteDrug administrationClinical oncologyAnnual meeting

SNMMI Elects Jean-Luc C Urbain, MD, PhD, FASNC, as President-Elect at 2024 Annual Meeting

SNMMI Elects Jean-Luc C Urbain, MD, PhD, FASNC, as President-Elect at 2024 Annual Meeting
itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUnited kingdomRegion flamandeWaals gewestCity ofWake forest universityNorth carolinaCleveland clinicFox chase cancer centerTemple university hospitalTemple universityBruxelles capitaleHeather jaceneCybil nielsenHarvard macy

Four key breakthroughs mean cancer won t be a death sentence

Four key breakthroughs mean cancer won t be a death sentence
dunyanews.tv - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dunyanews.tv Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesLawrence youngSun healthAmerican society of clinical oncologyCancer research united kingdomWeb deskAmerican societyClinical oncology

Trastuzumab Deruxtecan Effective For HR-Positive, HER2-Low Breast Cancer Treatment After Endocrine Therapy

Findings from ASCO 2024 suggest deruxtecan (T-DXd) may become a preferred first-line treatment for patients with hormone receptor (HR)-positive, HER2-low metastatic breast cancer that progressed after endocrine therapy.

United statesErical mayerCaffreym trastuzumabDaiichi sankyoGiuseppe curiglianoAmerican society of clinical oncologyDana farber cancer instituteEuropean institute of oncologyImage creditAmerican societyClinical oncologyEuropean institute